Actelion buys U.S.-based firm with cancer drug in development

ZURICH (Reuters) - Actelion said it will acquire Ceptaris, a privately held U.S.-based specialty pharmaceutical company developing a topical drug, Valchlor, to treat a form of cancer.

via Reuters: Health News Read More Here..